GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Cyclically Adjusted PB Ratio

Curis (CRIS) Cyclically Adjusted PB Ratio : 0.67 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Curis Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Curis's current share price is $14.47. Curis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $21.63. Curis's Cyclically Adjusted PB Ratio for today is 0.67.

The historical rank and industry rank for Curis's Cyclically Adjusted PB Ratio or its related term are showing as below:

CRIS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.17   Med: 2.07   Max: 9.29
Current: 0.67

During the past years, Curis's highest Cyclically Adjusted PB Ratio was 9.29. The lowest was 0.17. And the median was 2.07.

CRIS's Cyclically Adjusted PB Ratio is ranked better than
70.31% of 640 companies
in the Biotechnology industry
Industry Median: 1.715 vs CRIS: 0.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Curis's adjusted book value per share data for the three months ended in Dec. 2023 was $3.337. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $21.63 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Curis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Cyclically Adjusted PB Ratio Chart

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 5.22 3.17 0.42 0.59

Curis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.47 0.67 0.28 0.59

Competitive Comparison of Curis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Curis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PB Ratio falls into.



Curis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Curis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.47/21.63
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Curis's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.337/129.4194*129.4194
=3.337

Current CPI (Dec. 2023) = 129.4194.

Curis Quarterly Data

Book Value per Share CPI Adj_Book
201403 47.166 99.695 61.229
201406 45.825 100.560 58.976
201409 40.285 100.428 51.915
201412 34.620 99.070 45.226
201503 68.270 99.621 88.691
201506 62.759 100.684 80.671
201509 59.187 100.392 76.301
201512 50.012 99.792 64.860
201603 43.353 100.470 55.844
201606 35.676 101.688 45.405
201609 27.051 101.861 34.370
201612 20.738 101.863 26.348
201703 14.948 102.862 18.807
201706 6.414 103.349 8.032
201709 18.567 104.136 23.075
201712 14.616 104.011 18.186
201803 8.735 105.290 10.737
201806 4.286 106.317 5.217
201809 0.472 106.507 0.574
201812 -2.712 105.998 -3.311
201903 -8.283 107.251 -9.995
201906 -12.209 108.070 -14.621
201909 -15.672 108.329 -18.723
201912 -20.403 108.420 -24.355
202003 -22.016 108.902 -26.164
202006 -11.999 108.767 -14.277
202009 -10.099 109.815 -11.902
202012 28.561 109.897 33.635
202103 26.638 111.754 30.849
202106 24.559 114.631 27.727
202109 22.467 115.734 25.124
202112 19.795 117.630 21.779
202203 16.580 121.301 17.690
202206 13.515 125.017 13.991
202209 11.566 125.227 11.953
202212 9.637 125.222 9.960
202303 7.574 127.348 7.697
202306 5.279 128.729 5.307
202309 5.028 129.860 5.011
202312 3.337 129.419 3.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Curis  (NAS:CRIS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Curis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Curis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (CRIS) Business Description

Industry
Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421